Safety of biologic and synthetic targeted therapies in patients with immune-mediated diseases: data from the BIOBADAGUAY registry.

Objective: To analyze the safety of biologic (DMARDs-b) and synthetic targeted therapies (DMARDs-sd) in the BIOBADAGUAY registry (Paraguayan-Uruguayan registry of adverse events (AEs) in patients with inflammatory rheumatic diseases).

Methods: BIOBADAGUAY is a registry to prospectively evaluate the efficacy and safety of FAME-b and FAME-sd. The full methodology is available at https://biobadaguay.

Safety and Survival Associated with Biologic Therapies: First Report of the Biobadaguay on the Paraguayan-Uruguayan Registry of Adverse Events with Biologic Therapies.

Objective: Analyze adverse events (AE) and survival associated with biologic therapies (BT) in the Biobadaguay, the Paraguayan Uruguayan registry of adverse events.

Methods: Prospective, observational study of undetermined duration. Patients on BT at initiation and controls were included.